Skip to main content

Table 5 AE type and outcomes for AEs grade 1–3

From: Safety of thalidomide and bevacizumab in patients with hereditary hemorrhagic telangiectasia

 

AE grade

System Organ Class (SOC)/AE type

AE outcome

Treatment interruption

Improvement after interr

Treatment restart

Alternative cause for AE

  

General disorders

Vascular disorders

Musculo-Skeletal disorders

Nervous System & Psychiatric disorders

Renal disorders

Gastroint. disorders

Reproduct system disorders

Skin disorders

     

BZB

1

 

1 enlarged PAVM

1 joint pain

1 facial pain

    

2 hair loss

1 unresolved/worsened

4 resolved

1 Yes

4 No

1 No

1 No

In 2

2

1 fatigue

2 hypertension

6 joint pain

1 vertebral fracture

1 confusion

3 headaches

2 proteinuria

1 diarrhea

  

17 resolved

17 No

  

In 1

3

1 fatigue

3 hypertension

1 arterial thrombosisa

2 joint pain

1 confusion

 

1 GI bleedingb

1 diarrhea

  

1 unresolved/worsened

9 resolved

3 Yes

7 No

2 Yes

1 No

1 Yes

2 No

In 2

TH

1

   

5 peripheral neuropathyc

1 somnolence

1 drowsiness

   

1 rash

2 unresolved/worsened

6 resolved

3 Yes

5 No

3 Yes

3 No

none

2

   

5 peripheral neuropathyd

4 dizziness

2 somnolence

7 drowsiness

 

1 constipation

1 erectile dysfunction

 

7 unresolved/worsened

2 resolved with sequelae

11 resolved

15 Yes

5 No

10 Yes

5 No

15 No

none

3

1 limb edema

1 arterial thrombosisf

 

2 peripheral neuropathy &

2 dizziness

    

4 unresolved/worsened

2 resolved

4 Yes

2 No

2 Yes

2 No

1 Yes

3 No

In 1

  1. Legend: aunresolved/worsened after treatment interruption
  2. bresolved completely
  3. c3 resolved completely, 2 unresolved/worsened,
  4. d1 resolved completely, 1 resolved with sequelae, 3 unresolved/worsened
  5. &2 unresolved/worsened
  6. fresolved completely